JP2024535388A5 - - Google Patents

Info

Publication number
JP2024535388A5
JP2024535388A5 JP2024518651A JP2024518651A JP2024535388A5 JP 2024535388 A5 JP2024535388 A5 JP 2024535388A5 JP 2024518651 A JP2024518651 A JP 2024518651A JP 2024518651 A JP2024518651 A JP 2024518651A JP 2024535388 A5 JP2024535388 A5 JP 2024535388A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
subject
conjugate
compound according
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024518651A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024535388A (ja
Filing date
Publication date
Priority claimed from PCT/US2021/058495 external-priority patent/WO2022099159A1/en
Application filed filed Critical
Priority claimed from PCT/US2022/044765 external-priority patent/WO2023049475A1/en
Publication of JP2024535388A publication Critical patent/JP2024535388A/ja
Publication of JP2024535388A5 publication Critical patent/JP2024535388A5/ja
Pending legal-status Critical Current

Links

JP2024518651A 2021-09-26 2022-09-26 オリゴヌクレオチド組成物及びその方法 Pending JP2024535388A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163248520P 2021-09-26 2021-09-26
US63/248,520 2021-09-26
PCT/US2021/058495 WO2022099159A1 (en) 2020-11-08 2021-11-08 Oligonucleotide compositions and methods thereof
USPCT/US2021/058495 2021-11-08
US202263331756P 2022-04-15 2022-04-15
US63/331,756 2022-04-15
US202263397320P 2022-08-11 2022-08-11
US63/397,320 2022-08-11
PCT/US2022/044765 WO2023049475A1 (en) 2021-09-26 2022-09-26 Oligonucleotide compositions and methods thereof

Publications (2)

Publication Number Publication Date
JP2024535388A JP2024535388A (ja) 2024-09-30
JP2024535388A5 true JP2024535388A5 (cg-RX-API-DMAC7.html) 2025-10-07

Family

ID=85721200

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024518651A Pending JP2024535388A (ja) 2021-09-26 2022-09-26 オリゴヌクレオチド組成物及びその方法

Country Status (11)

Country Link
US (1) US20250333740A1 (cg-RX-API-DMAC7.html)
EP (1) EP4396354A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024535388A (cg-RX-API-DMAC7.html)
KR (1) KR20240063964A (cg-RX-API-DMAC7.html)
AU (1) AU2022352779A1 (cg-RX-API-DMAC7.html)
CA (1) CA3232070A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000856A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024005352A2 (cg-RX-API-DMAC7.html)
IL (1) IL311625A (cg-RX-API-DMAC7.html)
MX (1) MX2024003612A (cg-RX-API-DMAC7.html)
WO (1) WO2023049475A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
EP3094728B1 (en) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chiral design
CN117965536A (zh) 2015-07-22 2024-05-03 波涛生命科学有限公司 寡核苷酸组合物及其方法
MA46427A (fr) 2015-10-09 2018-08-15 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
US11013757B2 (en) 2016-06-03 2021-05-25 Wave Life Sciences Ltd. Oligonucleotides, compositions and methods thereof
WO2018098264A1 (en) 2016-11-23 2018-05-31 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
WO2018237194A1 (en) 2017-06-21 2018-12-27 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis
CN111108096A (zh) 2017-09-18 2020-05-05 波涛生命科学有限公司 寡核苷酸制备技术
JP2021521140A (ja) 2018-04-12 2021-08-26 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. オリゴヌクレオチド組成物及びその使用方法
CA3098624A1 (en) 2018-05-11 2019-11-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
AU2020241559A1 (en) 2019-03-20 2021-11-11 Wave Life Sciences Ltd. Technologies useful for oligonucleotide preparation
MX2021012981A (es) 2019-04-25 2022-01-18 Wave Life Sciences Ltd Composiciones de oligonucleotido y metodos de uso de las mismas.
WO2026077951A1 (en) 2024-10-07 2026-04-16 Vico Therapeutics B.V. Improved aon for rna editing
WO2026096688A1 (en) * 2024-10-30 2026-05-07 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008086524A2 (en) * 2007-01-11 2008-07-17 University Of Florida Research Foundation, Inc. Alpha-1-antitrypsin variants and uses thereof
EP3452596A4 (en) * 2016-05-04 2020-03-18 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
WO2020001793A1 (en) * 2018-06-29 2020-01-02 Eberhard-Karls-Universität Tübingen Artificial nucleic acids for rna editing
WO2020168135A1 (en) * 2019-02-13 2020-08-20 Beam Therapeutics Inc. Compositions and methods for treating alpha-1 antitrypsin deficiency
CA3154768A1 (en) * 2019-10-06 2021-04-15 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
JP2023548584A (ja) * 2020-11-08 2023-11-17 ウェイブ ライフ サイエンシズ リミテッド オリゴヌクレオチド組成物及びその方法

Similar Documents

Publication Publication Date Title
US7034133B2 (en) Oligonucleotide analogues
JP5677716B2 (ja) オリゴヌクレオチド類似体を含むキット及び方法並びにオリゴヌクレオチド類似体の使用
US8080644B2 (en) Oligonucleotide analogues
JP2022551124A5 (cg-RX-API-DMAC7.html)
JP2023548584A5 (cg-RX-API-DMAC7.html)
US5399676A (en) Oligonucleotides with inverted polarity
US5721218A (en) Oligonucleotides with inverted polarity
JP2004500330A (ja) グアニジニウム官能化オリゴマーとその製造法
JP2002527523A (ja) 機能付与したピリミジン誘導体
JPH05504553A (ja) 新規の結合を有するオリゴヌクレオチドアナログ
JPH09511250A (ja) 核酸治療に有用な修飾オリゴヌクレオチド及び中間体
AU2022352779A1 (en) Oligonucleotide compositions and methods thereof
CN1118140A (zh) 为提高在酸性pH的稳定性而改性的低聚核苷酸
JPH10509464A (ja) L−ヌクレオシド二量体組成物およびその治療目的の使用
JPH09506770A (ja) c−erbBの発現が関与する疾患を予防及び治療するためのアンチセンス核酸
WO2019182037A1 (ja) 毒性が低減されたアンチセンスオリゴヌクレオチド
CN119137272A (zh) 血管紧张素原调节组合物和其使用方法
Kiviniemi et al. Solid-supported 2′-O-glycoconjugation of oligonucleotides by azidation and click reactions
JP3142574B2 (ja) 2′,5′ホスホロチオエート/ホスホジエステルオリゴアデニレートおよびその抗ウィルス用途
AU2002325599B2 (en) Oligonucleotide analogues
Kvasyuk et al. Nucleotides. Part LVI. Synthesis and biological activity of modified (2′–5′) triadenylates containing 2′‐terminal 2′, 3′‐dideoxy‐3′‐fluoroadenosine derivatives
JP2025526994A5 (cg-RX-API-DMAC7.html)
Ademola Synthetic nucleotides and their biological applications
JPWO1996018640A1 (ja) アンチセンス核酸同族体